CRISPR gene editing is one of the most promising – and ethically controversial – new genetic technologies. One of the more recent examples of its promise: Cambridge startup Editas Medicine’s $120 million fund-raise.
We’ll discuss the potential of CRISPR along with the most important news of the week on MedHeads, MedCityNews.com’s look at the business of innovation in medicine.
MedHeads, as it does every Friday, starts at 4 pm Eastern today. Join us via the YouTube embed below or on our Google Hangout On Air page.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
MedCity News teammates Neil Versel, Meghana Keshavan and Nicole Oran will discuss the potential of CRISPR, the challenge of having Kim Kardashian endorse your FDA-approved drug, and the Google-DexCom partnership, among other topics.
So join the MedCity News team to talk about the week that was in the business of medicine at 4 pm Eastern today.
Photo: Wikimedia Commons
